A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer
International Federation of Gynecology and Obstetrics (FIGO) staging classification for stage IV epithelial ovarian cancer (EOC) separates stages IVA (pleural effusion) and IVB (parenchymal and/or extra-abdominal lymph node metastases). We aimed to evaluate its prognostic impact and to compare survi...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/3/706 |
| _version_ | 1797625006711111680 |
|---|---|
| author | Marie Métairie Louise Benoit Meriem Koual Enrica Bentivegna Henri Wohrer Pierre-Adrien Bolze Yohan Kerbage Emilie Raimond Cherif Akladios Xavier Carcopino Geoffroy Canlorbe Jennifer Uzan Vincent Lavoué Camille Mimoun Cyrille Huchon Martin Koskas Hélène Costaz François Margueritte Yohann Dabi Cyril Touboul Sofiane Bendifallah Lobna Ouldamer Nicolas Delanoy Huyen-Thu Nguyen-Xuan Anne-Sophie Bats Henri Azaïs |
| author_facet | Marie Métairie Louise Benoit Meriem Koual Enrica Bentivegna Henri Wohrer Pierre-Adrien Bolze Yohan Kerbage Emilie Raimond Cherif Akladios Xavier Carcopino Geoffroy Canlorbe Jennifer Uzan Vincent Lavoué Camille Mimoun Cyrille Huchon Martin Koskas Hélène Costaz François Margueritte Yohann Dabi Cyril Touboul Sofiane Bendifallah Lobna Ouldamer Nicolas Delanoy Huyen-Thu Nguyen-Xuan Anne-Sophie Bats Henri Azaïs |
| author_sort | Marie Métairie |
| collection | DOAJ |
| description | International Federation of Gynecology and Obstetrics (FIGO) staging classification for stage IV epithelial ovarian cancer (EOC) separates stages IVA (pleural effusion) and IVB (parenchymal and/or extra-abdominal lymph node metastases). We aimed to evaluate its prognostic impact and to compare survival according to the initial metastatic location. We conducted a multicenter study between 2000 and 2020, including patients with a FIGO stage IV EOC. Primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS) and recurrence rates. We included 307 patients: 98 (32%) had FIGO stage IVA and 209 (68%) had FIGO stage IVB. The median OS and PFS of stage IVA patients were significantly lower than those of stage IVB patients (31 versus 45 months (<i>p</i> = 0.02) and 18 versus 25 months (<i>p</i> = 0.01), respectively). Recurrence rate was higher in stage IVA than IVB patients (65% versus 47% (<i>p</i> = 0.004)). Initial pleural involvement was a poor prognostic factor with a median OS of 35 months versus 49 months for patients without initial pleural involvement (<i>p</i> = 0.024). Patients with FIGO stage IVA had a worse prognosis than patients with FIGO stage IVB EOC. Pleural involvement appears to be relevant for predicting survival. We suggest a modification of the current FIGO staging classification. |
| first_indexed | 2024-03-11T09:50:44Z |
| format | Article |
| id | doaj.art-10656d80935f477a8817383701ce5cd2 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T09:50:44Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-10656d80935f477a8817383701ce5cd22023-11-16T16:16:05ZengMDPI AGCancers2072-66942023-01-0115370610.3390/cancers15030706A Suggested Modification to FIGO Stage IV Epithelial Ovarian CancerMarie Métairie0Louise Benoit1Meriem Koual2Enrica Bentivegna3Henri Wohrer4Pierre-Adrien Bolze5Yohan Kerbage6Emilie Raimond7Cherif Akladios8Xavier Carcopino9Geoffroy Canlorbe10Jennifer Uzan11Vincent Lavoué12Camille Mimoun13Cyrille Huchon14Martin Koskas15Hélène Costaz16François Margueritte17Yohann Dabi18Cyril Touboul19Sofiane Bendifallah20Lobna Ouldamer21Nicolas Delanoy22Huyen-Thu Nguyen-Xuan23Anne-Sophie Bats24Henri Azaïs25AP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecological Oncological and Breast Surgery, Hôpital Européen Georges-Pompidou, 75015 Paris, FranceAP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecological Oncological and Breast Surgery, Hôpital Européen Georges-Pompidou, 75015 Paris, FranceAP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecological Oncological and Breast Surgery, Hôpital Européen Georges-Pompidou, 75015 Paris, FranceAP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecological Oncological and Breast Surgery, Hôpital Européen Georges-Pompidou, 75015 Paris, FranceAP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecological Oncological and Breast Surgery, Hôpital Européen Georges-Pompidou, 75015 Paris, FranceDepartment of Gynaecologic and Oncologic Surgery and Obstetrics, Lyon Sud University Hospital, Hospices Civils de Lyon, Université Lyon 1, 69002 Lyon, FranceCHU Lille, Department of Gynaecologic Surgery, University Lille, 59000 Lille, FranceDepartment of Obstetrics and Gynaecology, Institute Alix de Champagne University Hospital, 51100 Reims, FranceDepartment of Gynaecology, Hôpitaux Universitaires de Strasbourg, 67200 Strasbourg, FranceDepartment of Obstetrics and Gynaecology, Hôpital Nord, APHM, Aix-Marseille University (AMU), University Avignon, CNRS, IRD, IMBE, UMR 7263, 13397 Marseille, FranceAP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecological and Breast Surgery and Oncology, Pitié-Salpêtrière, 75013 Paris, FranceDepartment of Obstetrics Gynecology and Reproductive Medicine, University Paris Est Créteil, Centre Hospitalier Intercommunal de Créteil, 94000 Créteil, FranceDepartment of Gynaecological Surgery, INSERM U1085, équipe 8, CRLC Eugène Marquis, Université de Rennes 1, Hôpital Sud, CHU de Rennes, 35000 Rennes, FranceDepartment of Gynaecological Oncological and Breast Surgery—Université de Paris, Hôpital Lariboisière, 75010 Paris, FranceDepartment of Gynaecological Oncological and Breast Surgery—Université de Paris, Hôpital Lariboisière, 75010 Paris, FranceAP-HP (Assistance Publique des Hôpitaux de Paris), Division of Gynaecologic Oncology, Bichat University Hospital, 75018 Paris, FranceDepartment of Surgical Oncology, Georges-François Leclerc Centre, 21000 Dijon, FranceDepartment of Gynaecology, Centre Hospitalier Intercommunal de Poissy-Saint-Germain-en-laye, Site Hospitalier de Poissy, 78498 Poissy, FranceAP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecology ans Obstetrics, Hôpital Tenon, 75020 Paris, FranceAP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecology ans Obstetrics, Hôpital Tenon, 75020 Paris, FranceAP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecology ans Obstetrics, Hôpital Tenon, 75020 Paris, FranceDepartment of Gynaecology, Hôpital Universitaire de Tours, 37000 Tours, FranceAP-HP (Assistance Publique des Hôpitaux de Paris), Department of Medical Oncology, Hôpital Européen Georges-Pompidou, 75015 Paris, FranceAP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecological Oncological and Breast Surgery, Hôpital Européen Georges-Pompidou, 75015 Paris, FranceAP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecological Oncological and Breast Surgery, Hôpital Européen Georges-Pompidou, 75015 Paris, FranceAP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecological Oncological and Breast Surgery, Hôpital Européen Georges-Pompidou, 75015 Paris, FranceInternational Federation of Gynecology and Obstetrics (FIGO) staging classification for stage IV epithelial ovarian cancer (EOC) separates stages IVA (pleural effusion) and IVB (parenchymal and/or extra-abdominal lymph node metastases). We aimed to evaluate its prognostic impact and to compare survival according to the initial metastatic location. We conducted a multicenter study between 2000 and 2020, including patients with a FIGO stage IV EOC. Primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS) and recurrence rates. We included 307 patients: 98 (32%) had FIGO stage IVA and 209 (68%) had FIGO stage IVB. The median OS and PFS of stage IVA patients were significantly lower than those of stage IVB patients (31 versus 45 months (<i>p</i> = 0.02) and 18 versus 25 months (<i>p</i> = 0.01), respectively). Recurrence rate was higher in stage IVA than IVB patients (65% versus 47% (<i>p</i> = 0.004)). Initial pleural involvement was a poor prognostic factor with a median OS of 35 months versus 49 months for patients without initial pleural involvement (<i>p</i> = 0.024). Patients with FIGO stage IVA had a worse prognosis than patients with FIGO stage IVB EOC. Pleural involvement appears to be relevant for predicting survival. We suggest a modification of the current FIGO staging classification.https://www.mdpi.com/2072-6694/15/3/706epithelial ovarian cancerFIGO stage IVmetastatic patternsprognosispleural involvementoverall survival |
| spellingShingle | Marie Métairie Louise Benoit Meriem Koual Enrica Bentivegna Henri Wohrer Pierre-Adrien Bolze Yohan Kerbage Emilie Raimond Cherif Akladios Xavier Carcopino Geoffroy Canlorbe Jennifer Uzan Vincent Lavoué Camille Mimoun Cyrille Huchon Martin Koskas Hélène Costaz François Margueritte Yohann Dabi Cyril Touboul Sofiane Bendifallah Lobna Ouldamer Nicolas Delanoy Huyen-Thu Nguyen-Xuan Anne-Sophie Bats Henri Azaïs A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer Cancers epithelial ovarian cancer FIGO stage IV metastatic patterns prognosis pleural involvement overall survival |
| title | A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer |
| title_full | A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer |
| title_fullStr | A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer |
| title_full_unstemmed | A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer |
| title_short | A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer |
| title_sort | suggested modification to figo stage iv epithelial ovarian cancer |
| topic | epithelial ovarian cancer FIGO stage IV metastatic patterns prognosis pleural involvement overall survival |
| url | https://www.mdpi.com/2072-6694/15/3/706 |
| work_keys_str_mv | AT mariemetairie asuggestedmodificationtofigostageivepithelialovariancancer AT louisebenoit asuggestedmodificationtofigostageivepithelialovariancancer AT meriemkoual asuggestedmodificationtofigostageivepithelialovariancancer AT enricabentivegna asuggestedmodificationtofigostageivepithelialovariancancer AT henriwohrer asuggestedmodificationtofigostageivepithelialovariancancer AT pierreadrienbolze asuggestedmodificationtofigostageivepithelialovariancancer AT yohankerbage asuggestedmodificationtofigostageivepithelialovariancancer AT emilieraimond asuggestedmodificationtofigostageivepithelialovariancancer AT cherifakladios asuggestedmodificationtofigostageivepithelialovariancancer AT xaviercarcopino asuggestedmodificationtofigostageivepithelialovariancancer AT geoffroycanlorbe asuggestedmodificationtofigostageivepithelialovariancancer AT jenniferuzan asuggestedmodificationtofigostageivepithelialovariancancer AT vincentlavoue asuggestedmodificationtofigostageivepithelialovariancancer AT camillemimoun asuggestedmodificationtofigostageivepithelialovariancancer AT cyrillehuchon asuggestedmodificationtofigostageivepithelialovariancancer AT martinkoskas asuggestedmodificationtofigostageivepithelialovariancancer AT helenecostaz asuggestedmodificationtofigostageivepithelialovariancancer AT francoismargueritte asuggestedmodificationtofigostageivepithelialovariancancer AT yohanndabi asuggestedmodificationtofigostageivepithelialovariancancer AT cyriltouboul asuggestedmodificationtofigostageivepithelialovariancancer AT sofianebendifallah asuggestedmodificationtofigostageivepithelialovariancancer AT lobnaouldamer asuggestedmodificationtofigostageivepithelialovariancancer AT nicolasdelanoy asuggestedmodificationtofigostageivepithelialovariancancer AT huyenthunguyenxuan asuggestedmodificationtofigostageivepithelialovariancancer AT annesophiebats asuggestedmodificationtofigostageivepithelialovariancancer AT henriazais asuggestedmodificationtofigostageivepithelialovariancancer AT mariemetairie suggestedmodificationtofigostageivepithelialovariancancer AT louisebenoit suggestedmodificationtofigostageivepithelialovariancancer AT meriemkoual suggestedmodificationtofigostageivepithelialovariancancer AT enricabentivegna suggestedmodificationtofigostageivepithelialovariancancer AT henriwohrer suggestedmodificationtofigostageivepithelialovariancancer AT pierreadrienbolze suggestedmodificationtofigostageivepithelialovariancancer AT yohankerbage suggestedmodificationtofigostageivepithelialovariancancer AT emilieraimond suggestedmodificationtofigostageivepithelialovariancancer AT cherifakladios suggestedmodificationtofigostageivepithelialovariancancer AT xaviercarcopino suggestedmodificationtofigostageivepithelialovariancancer AT geoffroycanlorbe suggestedmodificationtofigostageivepithelialovariancancer AT jenniferuzan suggestedmodificationtofigostageivepithelialovariancancer AT vincentlavoue suggestedmodificationtofigostageivepithelialovariancancer AT camillemimoun suggestedmodificationtofigostageivepithelialovariancancer AT cyrillehuchon suggestedmodificationtofigostageivepithelialovariancancer AT martinkoskas suggestedmodificationtofigostageivepithelialovariancancer AT helenecostaz suggestedmodificationtofigostageivepithelialovariancancer AT francoismargueritte suggestedmodificationtofigostageivepithelialovariancancer AT yohanndabi suggestedmodificationtofigostageivepithelialovariancancer AT cyriltouboul suggestedmodificationtofigostageivepithelialovariancancer AT sofianebendifallah suggestedmodificationtofigostageivepithelialovariancancer AT lobnaouldamer suggestedmodificationtofigostageivepithelialovariancancer AT nicolasdelanoy suggestedmodificationtofigostageivepithelialovariancancer AT huyenthunguyenxuan suggestedmodificationtofigostageivepithelialovariancancer AT annesophiebats suggestedmodificationtofigostageivepithelialovariancancer AT henriazais suggestedmodificationtofigostageivepithelialovariancancer |